Neoantigen identification is based on in silico screening and prioritization using bioinformatics pipelines that score each candidate neoantigen on parameters such as allele class presentation, peptide processing by the proteasome, T cell receptor (TCR) binding, major histocompatibility complex (MHC) affinity, peptide-MHC (pMHC) stability, and tumor neoantigen source.12 This evidence concerns the gene HLA-C and neoplasm.